Lilly Wants Antibody EUA Expanded To Prevent COVID-19 In Nursing Homes

Eli Lilly will pursue an expanded emergency use authorization for its monoclonal antibody, bamlanivimab, the company said Friday (Jan. 22) as it revealed that data from an ongoing trial suggest the therapy reduced long-term care facility residents’ risk of contracting symptomatic COVID-19 by 80% compared with those who did not receive the therapy. Bamlanivimab, which is authorized for treatment of mild-to-moderate COVID-19 in adults and pediatric patients who have not been hospitalized, is currently used in nursing homes as a...